Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Leiden – page 17

401 clinical trials in Leiden, The Netherlands across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Leiden at a glance
401
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

401 trials in Leiden

Open in trial search

Osteogenesis imperfecta

Not yet recruiting

Phase 2 Study of AGA2115 in Adults with Osteogenesis Imperfecta (COL1A1/COL1A2 Variants) Evaluating Bone Density

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Angitia Inc. Ltd.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not yet recruiting

Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

Heart disease congenital

Not yet recruiting

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Chiesi Farmaceutici S.p.A.

Duchenne muscular dystrophy

Not yet recruiting

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Pancreatic carcinoma

Not yet recruiting

Phase II/III trial of autologous dendritic cells loaded with allogenic mesothelioma lysate in patients with borderline resectable pancreatic cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS DENDRITIC CELLS LOADED WITH ALLOGENIC ALLOGENEIC LYSATE OF MESOTHELIOMA CELL LINES
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Non-small cell lung cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merus B.V.

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Glioblastoma

Not yet recruiting

Phase 3 Randomized Study of Niraparib Tosilate Monohydrate vs. Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Neurotrials LLC

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Leiden

What the registry says about research in the country

01 Infectious Diseases Research

Innovative studies focusing on viral infections including trials evaluating vaccines against yellow fever, influenza, and mpox. Research includes assessment of antibody responses and vaccine effectiveness in different populations.

  • Influenza vaccine efficacy in elderly
  • Yellow fever prophylaxis
  • Mpox booster vaccination

Particular emphasis on preventive strategies and immune response evaluation.

02 Neurological Studies

Comprehensive research targeting neurological conditions, including investigations into Parkinson's disease treatments and neural response patterns. Studies examine innovative therapeutic approaches.

  • Parkinson's Disease treatments
  • CNS response analysis
  • Cerebral Amyloid Angiopathy

Focus on developing targeted therapies and understanding brain mechanisms.

03 Cancer and Chronic Conditions

Advanced research in oncology and chronic diseases, including studies on gastric cancer imaging and T-cell lymphoma treatments. Investigations into kidney disease management.

  • Advanced solid tumors
  • Gastric cancer diagnosis
  • Chronic kidney disease

Emphasis on innovative diagnostic techniques and treatment approaches.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.